CREBBP and malignant colon neoplasm: Among these agents, PRI-724 (a second-generation compound of ICG-001 and a low molecular weight inhibitor) binds specifically to CBP to disrupt the interaction between CBP and β-catenin, which leads to downregulation of β-catenin/TCF responsive gene expression, and induces apoptosis in colon cancer cells but not normal colonic epithelia cells [25].